The urokinase-type plasminogen activator (uPA) receptor (uPAR) functions in concert with co-receptors, including integrins, FPR-like receptor-1/lipoxin A4 receptor, and the epidermal growth factor receptor (EGFR), to initiate cell signaling. uPAR co-receptors may be dynamically organized into a multiprotein signaling receptor complex. In Chinese hamster ovary-K1 (CHO-K1) cells, uPA-binding to uPAR activates ERK/ MAP kinase, even though these cells do not express the EGFR; however, when CHO-K1 cells are transfected to express the EGFR, ERK activation becomes EGFR-dependent. In this study, we demonstrate that ERK activation in response to uPA follows equivalent biphasic kinetics in EGFR-expressing and -deficient CHO-K1 cells. In both cell types, the response is pertussis toxinsensitive; however, uPA promotes cell proliferation exclusively in the EGFR-expressing cells. uPA-induced mitogenic activity requires activation of both STAT5b and ERK. STAT5b was tyrosine-phosphorylated, in response to uPA, only in EGFR-expressing cells. uPA-induced cell proliferation was blocked by dominant-negative MEK1, dominant-negative STAT5b, and by expression of an EGFR that is mutated at Tyr-845, which is essential for STAT5b activation. In two cell culture models of uPAstimulated breast cancer growth, MDA-MB 468 cells treated with uPA and MCF-7 cells treated with uPAplasminogen activator inhibitor-1 complex, proliferation was completely inhibited when EGFR expression or activity was blocked. We conclude that expression and assembly of uPAR co-receptors in a specific cell type determines the response to uPA. The EGFR selectively cooperates with uPAR to mediate mitogenesis.
Receptor transactivation provides a mechanism by which an expanded continuum of signaling pathways may be activated in response to a single ligand. The epidermal growth factor receptor (EGFR) 1 plays a prominent role in transactivation events initiated by G protein-coupled receptors (GPCRs), integrins, and cytokine receptors (1) (2) (3) . Transactivated EGFR frequently is responsible for activating Ras and extracellular signal-regulated kinase/MAP kinase (ERK) (1) (2) (3) . EGFR transactivation may be ligand-dependent, in which case membrane-associated metalloproteases release EGFR ligands from their transmembrane anchors (4, 5) , or ligand-independent, due to the activity of intracellular kinases, such as c-Src, which cause EGFR tyrosine phosphorylation (6) . The urokinase receptor (uPAR) has two distinct ligands, urokinase-type plasminogen activator (uPA) and vitronectin, which activate distinct cell-signaling pathways. Vitronectin activates the small GTPase, Rac1, and thereby regulates downstream factors involved in new actin polymerization (7) (8) (9) . uPA activates multiple kinases and, perhaps most importantly, ERK (10 -13) . ERK activation occurs in response to low uPAR fractional occupancy, even in cells that express minimum amounts of uPAR, accounting for the role of uPAR autocrine signaling in determining the basal level of activated ERK in many cells (9, 13, 14) . In MCF-7 breast cancer cells, focal adhesion kinase (FAK) and c-Src are activated by uPA, upstream of ERK. Dominant-negative FAK and c-Src mutants completely block ERK activation in response to uPA (15) .
Because uPAR is linked to the cell surface by a glycosylphosphatidylinositol anchor, it is generally assumed that uPAR signals as part of a multiprotein signaling-receptor complex (MSRC). In support of this hypothesis, soluble uPAR has been shown to activate cell signaling similarly to uPA (15) (16) (17) (18) . Furthermore, multiple signaling receptors have been co-immunoprecipitated or co-localized with cell surface uPAR, including integrins, FPR-like receptor-1/lipoxin A4 receptor (FPRL-1), and the EGFR (7, 13, 19, 20) . Reagents that antagonize the signaling activities of these putative co-receptors or dissociate these receptors from uPAR counteract uPAR-initiated cell signaling (7, 13, 21) . However, the relationship between different proteins that participate in the uPAR MSRC remains incompletely understood. It is not clear whether all of the putative co-receptors must be simultaneously present to initiate cell signaling or whether co-receptors function interchangeably.
Furthermore, and perhaps most importantly, it is not clear whether variation in the composition of the uPAR MSRC alters cellular response to uPA.
We are particularly interested in physical and functional interactions involving uPAR and the EGFR, because both receptors have been strongly implicated in breast cancer progression (22) (23) (24) (25) . In HEp3, COS-7, and MCF-7 cells, EGFR tyrosine kinase antagonists block uPA-induced ERK activation (20, 26) . The EGFR co-immunoprecipitates with uPAR and with ␤1 integrin (20) ; however, the mechanism by which the EGFR supports uPAR-initiated ERK activation remains unclear. Evidence has been presented to suggest ligand-independent and -dependent mechanisms of EGFR transactivation by uPAR (20, 27) .
We recently reported that uPA activates ERK in Chinese hamster ovary (CHO)-K1 cells, despite the lack of endogenous EGFR (26) . When the EGFR was expressed in these cells, uPA still activated ERK; however, ERK activation was blocked by the EGFR tyrosine kinase antagonist, tyrphostin AG1478. Based on these data, we proposed a model in which the uPAR MSRC is dynamic in composition. When the EGFR is absent, alternative co-receptors function in the MSRC to activate the Ras-ERK pathway; however, when the EGFR is expressed, the EGFR assumes a dominant role and becomes essential for uPA-initiated signaling to ERK.
Herein, we report that EGFR expression in CHO cells modifies the cellular response to uPA, so that uPA functions as a mitogen. Importantly, the effects of EGFR expression do not reflect a change in the kinetics of ERK activation in response to uPA. Instead, the EGFR supports uPA mitogenic activity by recruiting and activating STAT5b downstream of uPAR. STAT5b has been previously implicated in EGF-triggered cell growth (28) . Our results support a model in which STAT5b and ERK function independently, but in a complementary manner, to promote cell growth. We have extended this observation to breast cancer cells and find that EGFR is uniformly necessary for uPA-induced growth. We conclude that the composition of the uPAR MSRC is critical in determining cellular response to uPA.
EXPERIMENTAL PROCEDURES
Reagents and Proteins-High molecular weight two-chain uPA was provided by Drs. Jack Henkin and Andrew Mazar (Abbott Laboratories, Abbott Park, IL) and inactivated with diisopropyl fluorophosphate to form DIP-uPA, as previously described (10) . Human plasminogen activator inhibitor-1 (PAI-1) was from Molecular Innovations, Inc. (Southfield, MI). uPA⅐PAI-1 complex was prepared by reacting twochain uPA (0.2 M) with an equimolar concentration of PAI-1 for 10 min at 37°C. Reaction was confirmed by loss of uPA activity against L-pyroglutamylglycylarginine-p-nitroanilide. Recombinant human EGF was from R&D systems (Minneapolis, MN). Tyrphostin AG1478 and GM6001 were from EMD Biosciences, Inc. (San Diego, CA). Batimastat was kindly provided by Dr. Jay Fox (University of Virginia). Pertussis toxin was from List Biological Laboratories, Inc. (Campbell, CA). uPARspecific antibody 399R was from American Diagnostica, Inc. (Greenwich, CT). Phosphorylated ERK-specific antibody was from Cell Signaling Technologies (Beverly, MA). Total ERK-specific polyclonal antibody was from Zymed Laboratories, Inc. (San Francisco, CA). EGFR-specific antibody was from Upstate Biotechnology (Lake Placid, NY). STAT5b-specific antibody (G-2) was from Santa Cruz Biotechnologies (Santa Cruz, CA). Phosphotyrosine-specific antibody PY20 was from BD Biosciences. Bromodeoxyuridine (BrdUrd)-specific monoclonal antibody conjugated with Alexa Fluor 594 was from Molecular Probes, Inc. (Eugene, OR). Expression constructs encoding dominant negative MEK1, green fluorescent protein (GFP) (11), wild-type EGFR (WT-EGFR), mutant EGFRs (K721A and Y845F) (29, 30) , and dominant-negative STAT5b (28, 31) are previously described. The double-EGFR mutant, EGFR-K721A/Y845A, was prepared by site-directed mutagenesis using the QuikChange system by Stratagene (Cedar Creek, TX).
Cell Lines-CHO-K1 cells were obtained from the ATCC and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (HyClone), penicillin (100 units/ml), streptomycin (100 g/ml), and non-essential amino acids (0.1 mM). CHO-K1 cells, with stable overexpression of WT-EGFR (WT-EGFR-CHO cells), were previously described (26) . MDA-MB 468 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 g/ml). Low passage MCF-7 cells were cultured in RPMI supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 g/ml). All cells were passaged using Trypsin-EDTA (Invitrogen) and maintained in culture for at least 18 h before performing experiments.
EGFR Knock-down with siRNA-The target sequence for human EGFR-specific double-stranded siRNA was determined by analyzing the cDNA sequence in the region from 50 -100 nucleotides downstream of the start codon. The chosen sequence (aacucuggaggaaaagaaagu) fits the pattern aa(N19)tt with ϳ50% GC content and corresponds to nucleotides 317-336 of the coding region. The siRNA sequence was subjected to a Blast search to optimize specific silencing. Duplex siRNA was synthesized by Dharmacon (Lafayette, CO). siCONTROL non-targeting siRNA pool also was from Dharmacon. siRNA (0.2 M) was introduced into WT-EGFR-CHO cells and MDA-MB 468 cells by incubation with Oligofectamine (Invitrogen) in serum-free medium for 4 h. Control cells were treated with transfection reagent alone. Transfected cultures were allowed to recover in serumcontaining medium, according to the manufacturer's instructions.
Detection of EGFR, uPAR, Tyrosine-phosphorylated STAT5b, and Activated ERK-To detect EGFR in siRNA-treated WT-EGFR-CHO cells, cell extracts were prepared in 10 mM HEPES, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Nonidet P-40, pH 7.5, containing protease inhibitor mixture (Sigma-Aldrich). The concentration of protein in each extract was determined by bicinchoninic acid assay. Equal amounts of cell extract (20 g of protein) were subjected to SDS-PAGE, electro-transferred to nitrocellulose membranes, and probed with EGFR-specific antibody. The blots were probed for total ERK as a control for load.
To detect uPAR in EGFR siRNA-treated cells, cell extracts were prepared in ice-cold radioimmune precipitation assay (RIPA) buffer (20 mM sodium phosphate, 150 mM NaCl, pH 7.4, 1% Nonidet P-40, 0.1% SDS, 0.2% deoxycholic acid) containing protease inhibitor mixture. Immunoprecipitates were prepared from equal amounts of cell extracts (1 mg), after pre-clearing with protein G-agarose, using antibody 399R. Immunoprecipitates were washed three times with RIPA buffer and subjected to immunoblot analysis for uPAR. An equivalent immunoprecipitation approach was used to detect EGFR and mutants thereof (K721A and Y845F) in transiently transfected cells. In these studies, cell extracts were prepared 24 h after introduction of the constructs. To detect phosphorylated STAT5b, cell extracts in RIPA buffer containing protease inhibitor mixture and sodium orthovanadate (1 mM) were immunoprecipitated with STAT5b-specific antibody. The immunoprecipitates were subjected to immunoblot analysis and probed with phosphotyrosine-specific antibody PY20. Blots were re-probed for total STAT5b as a control for load.
To examine ERK activation, CHO-K1 and WT-EGFR-CHO cells were maintained in serum-free medium for 18 h, at which time the confluency was 80 -90%. Some cultures were pre-treated with tyrphostin AG1478 for 2 h, pertussis toxin for 2 h, GM6001 for 1 h, or batimastat for 1 h, immediately prior to adding uPA or EGF for the indicated times. Cell extracts were prepared and probed for phosphorylated and total ERK.
Cell Growth-Cell growth was measured by MTT assay, using the Cell Proliferation Kit I (Roche Applied Science), which provides an index of viable cell number. Cells (5000/well) were plated in 96-well plates and cultured for 18 h in serum-containing medium. siRNAtreated cultures were maintained in serum-containing medium for 24 h prior to transfer to 96-well plates. All cells were washed with serumfree medium and then serum-starved for 4 h. Some cultures were treated with tyrphostin AG1478 or uPAR-specific antibody 399R (25 g/ml) for 2 h as previously described (14, 26) , immediately prior to adding uPA (10 nM), or EGF (10 ng/ml) in 1% FBS-containing medium for 48 h. MTT hydrolysis was determined based on absorbance at 570 nm. Control cultures were maintained in 1% FBS-containing medium without uPA or EGF. In each experiment, MTT assays were performed to determine viable cell number prior to the 48-h incubation. The presented results show the change in cell number over the 48-h culture period.
BrdUrd Incorporation-DNA synthesis was measured by BrdUrd incorporation, as previously described (30) . CHO-K1 cells and WT-EGFR-CHO cells were plated on sterile coverslips in 12-well plates. The cells were co-transfected with pEGFP, to express GFP, and with plasmids encoding either WT-EGFR, kinase-inactive EGFR (EGFR-K721A), EGFR-Y845F, EGFR-K721A/Y845A, dominant-negative MEK1, or dominant-negative STAT5b, at a ratio of 1:4, using FuGENE 6 (Roche Applied Science). Transfections were performed in serumcontaining medium, as directed by the manufacturer. Cells were cultured for 18 h, washed with serum-free medium, and then cultured in serum-free medium for 4 h, prior to adding DIP-uPA (10 nM) or EGF (10 ng/ml) and BrdUrd (100 M) in 1% FBS-containing medium. Incubations were conducted for an additional 18 h. Cells were then fixed with 4% formaldehyde and treated with 2 M HCl for 1 h at 37°C. Fixed cells were incubated with BrdUrd-specific antibody conjugated with Alexa Fluor 594 (1:50). DNA synthesis was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd. When cultures were maintained in 1% FBS for 18 h, 52 Ϯ 4% of CHO-K1 cells were BrdUrd-positive. Under the same conditions, 43 Ϯ 4% of the WT-EGFR-CHO cells were BrdUrd-positive. These baselines allowed detection of increases or decreases in DNA synthesis. All results are expressed as the -fold increase of the BrdUrd incorporation relative to cells maintained in 1% FBS. The maximum theoretical response was ϳ2.0-fold. Statistical significance was determined by unpaired t test.
Co-transfection efficiencies were determined by immunofluorescence microscopy. CHO-K1 cells were co-transfected with pEGFP and with plasmids encoding WT-EGFR, EGFR-K721A, EGFR-Y845F, or EGFR-K721A/Y845A and fixed in 4% formaldehyde. Fixed cells were incubated with EGFR-specific antibody (1:1000) overnight. The cells were then washed and incubated with secondary antibody conjugated with Alexa Fluor 568 (1 g/ml). Co-transfection was demonstrated by the presence of red and green fluorescence in the same cells and was always Ͼ95%.
RESULTS

Co-receptor Function in uPAR-initiated Signaling to ERK-
Our previous studies in MCF-7, HT-1080, and MDA-MB-231 cells demonstrated that uPA activates ERK, that this response does not require uPA proteolytic activity, and that ERK activation, together with the resulting changes in cell migration and proliferation, are blocked by inhibiting uPA binding to uPAR (10, 11, 14) . In CHO-K1 cells, DIP-uPA activates ERK even though these cells do not express the EGFR; however, when CHO-K1 cells are transfected to express EGFR, signaling from uPAR to ERK becomes EGFR-dependent (26) . FPRL-1 and/or related GPCRs have been identified as essential uPAR signaling co-receptors, like the EGFR (19) . Thus, we tested whether FPRL-1-related receptors are essential for uPA-initiated ERK activation in CHO-K1 cells. The cells were pretreated with 100 ng/ml pertussis toxin for 2 h, which inhibits the activity of FPRL-1 (19) , and then stimulated with 10 nM DIP-uPA. As shown in Fig. 1A , pertussis toxin blocked ERK activation, implicating FPRL-1 or a similar G i -binding GPCR.
Next, we tested WT-EGFR-CHO cells, which were previously characterized (26) . If the EGFR and FPRL-1 function interchangeably, then these cells would be expected to be pertussis toxin-insensitive; however, this was not the case. The EGFRspecific inhibitor, tyrphostin AG1478, inhibited ERK activation, supporting our earlier findings (26); however, pertussis toxin also completely blocked ERK phosphorylation. These data suggest that the EGFR does not displace or negate the need for FPRL-1-related receptors in the uPAR MSRC in CHO cells.
In breast cancer cell lines, uPAR-specific antibody 399R binds to uPAR, blocks uPA-binding, and inhibits ERK activation together with resulting changes in cell physiology (11, 14) . To test whether ERK activation by uPA requires uPAR in WT-EGFR-CHO, we pre-treated cells with antibody 399R or with control IgG. Antibody 399R blocked ERK activation, confirming a necessary role for uPAR in these cells (Fig. 1B) .
uPA Promotes Growth of CHO Cells That Express EGFR-To test whether the EGFR alters the cellular response to uPA, we compared CHO-K1 and WT-EGFR-CHO cells. Initially we studied cell growth, using the MTT assay, which measures the total number of viable cells (32) , and thus reflects both cell proliferation and cell death. CHO-K1 cells that were maintained in 1.0% FBS for 48 h demonstrated a 33 Ϯ 3% increase in number (p Ͻ 0.01); however, neither DIP-uPA (10 nM) nor EGF (10 ng/ml) increased growth further (Fig. 2) . The lack of response to EGF was anticipated, given the absence of the EGFR.
When WT-EGFR-CHO cells were maintained in 1.0% FBS for 48 h, an 18 Ϯ 2% increase in cell number was detected; however, EGF increased cell growth 4.1-fold (p Ͻ 0.01), compared with the control. More importantly, DIP-uPA increased growth nearly 5-fold (p Ͻ 0.01), suggesting that EGFR expression converts uPA into a CHO cell mitogen. The effects of uPA on WT-EGFR-CHO cell growth were inhibited by ϳ90% when antibody 399R was added, suggesting that uPA binding to uPAR is required. Antibody 399R did not significantly affect cell growth in the absence of DIP-uPA. When cells were treated with EGF and DIP-uPA in combination, cell growth was not significantly increased compared with the level observed when either agent was added alone (results not shown). The results of these MTT assays suggest that the EGFR modifies the cellular response to uPA, so that uPA is either mitogenic and/or anti-apoptotic.
To confirm that the EGFR is necessary for uPA-induced growth in WT-EGFR-CHO cells, a number of strategies were applied. Fig. 3A shows that tyrphostin AG1478 blocked cell growth in response to both EGF and uPA. Next, we used EGFR-specific siRNA to knock-down EGFR in WT-EGFR-CHO cells. Fig. 3B shows that EGFR expression was substantially decreased from 48 -96 h, after siRNA introduction, compared with cells that were treated with transfection reagent alone. In control experiments, we showed that uPAR expression was not affected (Fig. 3B) . As shown in Fig. 3C , EGFR knock-down blocked cell growth in response to EGF and uPA. siCONTROL A, CHO-K1 and WT-EGFR-CHO cells were cultured in serum-free medium for 18 h. The cells were pretreated with either pertussis toxin (PTX) (100 ng/ml) or tyrphostin AG1478 (0.5 M) for 2 h before treatment with DIP-uPA (10 nM) for 10 min. Cell extracts were obtained and subjected to immunoblot analysis to determine phosphorylated ERK (P-ERK) and total ERK. B, WT-EGFR-CHO cells were cultured in serum-free medium for 18 h. The cells were pretreated with uPAR-specific antibody (399R, 25 g/ml) or with rabbit IgG (25 g/ml) for 2 h and then with DIP-uPA (10 nM) for 10 min. Cell extracts were obtained and subjected to immunoblot analysis to determine P-ERK and total ERK. non-targeting siRNA pool had no effect. Taken together, these results confirm that the EGFR is necessary for uPA-stimulated growth in WT-EGFR-CHO cells.
Next, we examined whether expression of EGFR in CHO-K1 cells alters the kinetics of ERK phosphorylation. The effects of ERK activation on cell physiology are strongly dependent on the kinetics of the response (33) (34) (35) . Cells were serum-starved for 18 h and then treated with 10 nM DIP-uPA. The pattern of response was equivalent in both CHO-K1 and WT-EGFR-CHO cells (Fig. 4) . DIP-uPA induced a substantial increase in phosphorylated ERK by 10 min followed by a decline to basal levels or below at 30 min. This was followed by a second phase of ERK phosphorylation, which was apparent by 60 min and sustained through at least 6 h. Thus, ERK activation in response to DIP-uPA is biphasic in CHO-K1 and WT-EGFR-CHO cells. Biphasic ERK activation has been demonstrated previously with other ligands (36); however, because CHO-K1 and WT-EGFR-CHO cells demonstrated equivalent ERK activation kinetics, the effects of EGFR expression on cellular response to uPA cannot be explained by this signaling pathway.
Transient EGFR Expression in CHO Cells Permits Mitogenesis in Response to uPA-To confirm that uPA is mitogenic in CHO-K1 cells only when EGFR is expressed, we applied a transient transfection strategy and measured BrdUrd incorporation as an index of DNA synthesis in S-phase. CHO-K1 cells were co-transfected to express WT-EGFR and GFP, as a transfection marker, or GFP alone. BrdUrd uptake was determined by immunofluorescence microscopy. Fig. 5 shows that cells transfected to express GFP alone failed to demonstrate a statistically significant increase in BrdUrd incorporation in response to EGF or uPA. By contrast, cells that were transfected to express EGFR and GFP demonstrated a significant increase in BrdUrd incorporation in response to both EGF and uPA (p Ͻ 0.01). The response to uPA confirms that uPA is mitogenic in CHO cells only when these cells express EGFR.
Our results suggest that the EGFR permits mitogenesis in response to uPA without modifying ERK activation kinetics. To test whether ERK activation is necessary for uPA-mediated WT-EGFR-CHO cell proliferation, we examined BrdUrd incorporation in cells that were transfected to express dominantnegative MEK1. Fig. 6 shows that dominant-negative MEK1 had no effect on growth in 1% FBS, but completely blocked WT-EGFR-CHO cell growth in response to uPA and EGF. Thus, ERK activation is essential for uPA-induced growth in CHO cells.
The Roles of Src and STAT5b in uPA-induced MitogenesisExperiments were performed to probe the mechanism by which the EGFR converts uPA into a mitogen. Nude mice that overexpress EGFR and c-Src show a synergistic increase in tumorigenesis, and it has been proposed that the synergy results from the ability of c-Src to induce phosphorylation of Tyr-845 in the EGFR, which leads to activation of STAT5b (28, 30, 37) . We previously demonstrated that c-Src is necessary for uPA-mediated ERK activation in MCF-7 cells (15) . To test the role of c-Src in uPA-induced WT-EGFR-CHO cell growth, we transfected cells to express dominant-negative c-Src; however, cell death resulted (results not shown). Similarly, the Src family kinase inhibitor, PP2 (0.5 M), was highly toxic in CHO-K1 and WT-EGFR-CHO cells (results not shown). These results suggest that basal Src activity is essential for CHO cell survival.
Next, we transiently transfected CHO-K1 cells to express EGFR mutants with previously characterized modifications in FIG. 2 . uPA increases viable cell number selectively in EGFRexpressing CHO cells. CHO-K1 and WT-EGFR-CHO cells were serum-starved for 4 h. The cells then were incubated with uPA (10 nM) or EGF (10 ng/ml) in 1% FBS-containing medium for 48 h or cultured in 1% FBS alone (control or "Con"). uPAR-specific antibody (399R, 25 g/ml) was included in the cultures, as indicated. The number of viable cells was determined by MTT assay before (0 h) and after (48 h) the 48-h incubation period. Cell number is expressed as the percent increase in viable cells relative to the 0-h point (mean Ϯ S.E., n ϭ 10).
FIG. 3. EGFR activity is necessary for uPA-induced cell growth.
A, WT-EGFR-CHO cells were serum-starved for 4 h. The cells then were treated with 0.5 M tyrphostin AG1478 (ϩ) or with vehicle (Ϫ) for 2 h and then with DIP-uPA (10 nM) or EGF (10 ng/ml) for 48 h. The number of viable cells was determined by MTT assay before (0 h) and after (48 h) incubation with uPA or EGF. Cell number is expressed as the percent increase in viable cells (mean Ϯ S.E., n ϭ 10). B, WT-EGFR-CHO cells were plated in 60-mm dishes. After 18 h, EGFRspecific siRNA (200 nM) was introduced by transfection. The cells were rescued in serum-containing medium for an additional 20 -92 h. Control cells were treated with transfection reagent alone (indicated as "Ϫ"). Cell extracts were subjected to immunoblot analysis to detect EGFR and total ERK as a control for load. Cell extracts were also subjected to immunoprecipitation and then immunoblot analysis with uPAR-specific antibody 399R to detect uPAR. C, WT-EGFR-CHO cells were plated on 60-mm dishes and treated with EGFR-specific siRNA (200 nM) or control siRNA pool (200 nM). After 24 h, the cells were transferred to 96-well plates and cultured for an additional 18 h. The cultures then were serum-starved for 4 h and treated with DIP-uPA (10 nM) or EGF (10 ng/ml) for 48 h. The number of viable cells was determined by MTT assay before (0 h) and after (48 h) incubation with EGF or uPA. Cell number is expressed as the percent increase in viable cells (mean Ϯ S.E., n ϭ 10). function. BrdUrd incorporation was then determined. As shown in Fig. 7A , none of the EGFR mutants affected BrdUrd incorporation in the absence of uPA. In cells that were transfected to express the WT-EGFR, uPA increased BrdUrd incorporation, as anticipated. No response to uPA was observed in cells transfected to express kinase-inactive EGFR (EGFR-K721A) or in cells transfected to express EGFR-Y845F, which fails to activate STAT5b in response to EGF (28) . Fig. 7B shows the results of control experiments demonstrating that wild type and mutant EGFRs were expressed at comparable levels.
We also examined the ability of the EGFR mutants to express dominant-negative activity in WT-EGFR-CHO cells (Fig.  7C) . All of the EGFR mutants, including EGFR-K721A, EGFR-Y845F, and EGFR-K721A/Y845F, blocked BrdUrd incorporation in response to uPA and EGF. The mutants did not significantly alter BrdUrd incorporation in control cells that were maintained in 1.0% FBS. These studies suggest an important role for EGFR kinase activity and for Tyr-845 in the pathway by which uPAR ligation leads to cell proliferation.
To further test the role of STAT5b in the pathway by which uPA induces cell growth, WT-EGFR-CHO cells were transfected to express dominant-negative STAT5b, a C-terminally truncated STAT5b that dimerizes with wild type STAT5b. Fig.  8A shows that BrdUrd incorporation in response to both EGF and uPA was blocked in these cells. Next, we tested whether FIG. 4 . CHO-K1 and WT-EGFR-CHO cells demonstrate biphasic ERK activation kinetics in response to uPA. Cells were incubated in serum-free medium for 18 h and then treated with DIP-uPA (10 nM) for the indicated times. Cell extracts were prepared and subjected to immunoblot analysis to detect phosphorylated ERK (P-ERK) and total ERK.
FIG. 5. uPA promotes growth of CHO-K1 cells that transiently express EGFR.
CHO-K1 cells were transiently transfected with plasmids encoding WT-EGFR and GFP or GFP alone. After 18 h, the cells were transferred to serum-free medium for 4 h. Cells were treated with DIP-uPA (10 nM) or EGF (10 ng/ml) and BrdUrd (100 M) in medium containing 1% FBS for 18 h. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd. In the absence of uPA and EGF, 52 Ϯ 4% of CHO-K1 cells were BrdUrdpositive (first bar). Cell growth was expressed as the -fold increase in BrdUrd incorporation relative to the first bar. The double asterisk indicates that the value is significantly different at the level of p Ͻ 0.01 (mean Ϯ S.E., n ϭ 6).
FIG. 6. ERK activation is necessary for uPA-induced cell growth.
WT-EGFR-CHO cells were transiently transfected with plasmids encoding dominant-negative MEK1 and GFP or GFP alone. After 18 h, the cells were cultured for 4 h in serum-free medium and then treated with either DIP-uPA (10 nM) or EGF (10 ng/ml) and BrdUrd (100 M) in 1% FBS-containing medium for an additional 18 h. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd. When WT-EGFR-CHO cells were maintained in 1% FBS without uPA or EGF for 18 h (first bar), 43 Ϯ 4% of the cells were BrdUrd-positive. Cell growth was expressed as the -fold increase of the BrdUrd incorporation relative to the first bar (mean Ϯ S.E., n ϭ 6).
FIG. 7. The activity of EGFR mutants in supporting uPA-induced growth.
A, CHO-K1 cells were transiently co-transfected with plasmids encoding GFP and WT-EGFR, EGFR-K721A, or EGFR-Y845F. After 18 h, the cells were washed with serum-free medium and maintained in serum-free medium for 4 h. The cells were then treated with DIP-uPA (10 nM) or vehicle and BrdUrd (100 M) in 1% FBScontaining medium for 18 h. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd and expressed as the -fold increase in BrdUrd incorporation relative to cells that were transfected with pEGFP alone and maintained in 1% FBS (Con) (mean Ϯ S.E., n ϭ 6). B, CHO-K1 cells were transiently transfected with constructs encoding WT-EGFR, EGFR-K721A, or EGFR-Y845F, or empty vector. After 24 h, equal amounts of cell extract were immunoprecipitated with EGFR-specific antibody. The immunoprecipitates were subjected to immunoblot analysis to detect EGFR expression. C, WT-EGFR-CHO cells were transiently transfected with plasmids encoding EGFR-K721A, EGFR-Y845F, or EGFR-K721A/Y845F. After 18 h, the cells were serum-starved for 4 h. The cells were then treated with DIP-uPA (10 nM) or EGF (10 ng/ml) and BrdUrd (100 M) in 1% FBS-containing medium for 18 h. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd and normalized to the level of BrdUrd incorporation in cells that were transfected with pEGFP only and maintained in 1% FBS (mean Ϯ S.E., n ϭ 6).
uPA induces tyrosine phosphorylation of STAT5b. We immunoprecipitated STAT5b from extracts of CHO-K1 and WT-EGFR-CHO cells 10 min after treatment with EGF (10 ng/ml) or uPA (10 nM). EGF induced modest but significant tyrosine phosphorylation of STAT5b, only in WT-EGFR-CHO cells, as anticipated (Fig. 8B ). uPA induced a similar level of STAT5b tyrosine phosphorylation in WT-EGFR-CHO cells and failed to induce STAT5b phosphorylation in CHO-K1 cells. Thus, uPA activates STAT5b in an EGFR-dependent manner.
Role of MMPs in uPA-initiated ERK Activation-It has been reported that the EGFR is transactivated downstream of uPAR by MMP-dependent (27) or -independent mechanisms (20) . The MMP-dependent mechanism has been reported to involve release of membrane-anchored EGFR ligands (38) . To test the role of MMPs in the pathway by which uPAR ligation leads to WT-EGFR-CHO cell growth, we pretreated cells with the general MMP inhibitors, GM6001 and batimastat. The cells were then treated with uPA or, as a control, EGF. ERK phosphorylation was measured. The MMP inhibitors had no effect on ERK activation by EGF, as anticipated (Fig. 9) ; however, GM6001 and batimastat decreased uPA-induced ERK phosphorylation. Batimastat entirely blocked ERK phosphorylation, whereas the effects of GM6001 were incomplete; however, substantial inhibition was still observed. These results support a model in which MMPs play an important role in uPAR signaling to ERK in WT-EGFR-CHO cells.
EGFR Is Required for uPA-promoted Cell Growth in Breast Cancer Cells-uPAR and the EGFR are both associated with a poor prognosis in breast cancer (22, 23, 25) . Our results suggest a novel relationship between these two receptors, in which the EGFR augments uPAR signaling by activation of STAT5b and thus converts uPA into a mitogen. In the next series of studies, we tested whether the same relationship exists in breast cancer cells. We used immunoblot analysis to demonstrate that MDA-MB 468 breast cancer cells express high levels of EGFR, as previously reported (28), and uPAR (results not shown). Both uPA and EGF induced growth in these cells, as determined by MTT assay (p Ͻ 0.05) (Fig. 10) . EGFR-specific siRNA reduced EGFR expression by Ͼ90%, as determined by immunoblot analysis (results not shown), and blocked growth in response to EGF. Importantly, EGFR-specific siRNA also blocked MDA-MB 468 cell growth in response to uPA, whereas siCONTROL non-targeting siRNA pool had no effect.
We previously reported that uPA⅐PAI-1 complex promotes growth of MCF-7 breast cancer cells, whereas free uPA and free PAI-1 do not (39) . The effects of uPA⅐PAI-1 complex on growth result from the recruitment of uPAR and a second receptor, the very low density lipoprotein (VLDL) receptor, which is a member of the LDL receptor family, to a common receptor complex. Recruitment of the VLDL receptor leads to sustained activation of ERK, which is critical for MCF-7 cell growth. In new studies, we tested whether the EGFR is also necessary for uPA⅐PAI-1 complex-promoted growth. As shown in Fig. 11 , uPA⅐PAI-1 complex promoted MCF-7 cell growth, as previously reported (39) , and tyrphostin AG1478 blocked the response, suggesting a necessary role for the EGFR.
DISCUSSION
The EGFR is essential for normal development (40, 41) . In cancer, EGFR overexpression is frequently observed and has been associated with a poor prognosis. This is particularly evident in breast cancer, which demonstrates EGFR overexpression with a frequency exceeding 30% (22, 23, 42) . The importance of the EGFR may reflect potent autocrine and paracrine signaling pathways; however, the EGFR is also a major target for receptor transactivation (1-3, 43) .
uPAR expression also carries substantial prognostic significance in cancer, and there is considerable overlap between the cancers in which uPAR and the EGFR have been implicated (25) . Once again, breast cancer has been a focus for considerable study and both uPA and uPAR have been implicated in progression, recurrence, and metastasis (22, 23, 25) . Unlike the EGFR, low levels of uPAR expression may be sufficient to adversely affect breast cancer progression. uPAR promotes cancer progression by organizing a cell-surface protease cascade, which facilitates cancer cell penetration of extracellular matrix boundaries (24) ; however, there is also evidence that A, WT-EGFR-CHO cells were transiently transfected with plasmids encoding GFP and dominant-negative STAT5b. After 18 h, the cells were washed with serum-free medium and maintained in serumfree medium for 4 h. The cells were then treated with either DIP-uPA (10 nM) or EGF (10 ng/ml) and BrdUrd (100 M) in 1% FBS-containing medium for 18 h. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdUrd and expressed as the -fold increase of the BrdUrd incorporation relative to cells maintained in 1% FBS (mean Ϯ S.E., n ϭ 6). B, CHO-K1 and WT-EGFR-CHO cells were maintained in serum-free medium for 18 h and then treated with DIP-uPA (10 nM) or EGF (10 ng/ml) for 10 min. STAT5b was isolated by immunoprecipitation. The immunoprecipitates were then subjected to immunoblot analysis to detect phosphorylated and total STAT5b. alternative mechanisms are operational. For example, expression of PAI-1, the primary uPA protease inhibitor, unexpectedly is associated with a negative prognosis in breast cancer (44, 45) .
As an alternative to the matrix-proteolysis model, uPARinitiated cell signaling may play an important role in determining the adverse effects of uPAR, uPA, and PAI-1 in cancer progression. We and others have shown that uPAR signaling to ERK is exquisitely sensitive to low concentrations of uPA and thus a key determinant of the basal level of ERK phosphorylation in some cancer cells (9, 13) . Aguirre-Ghiso et al. (46) demonstrated a correlation between uPAR expression and the transition from tumor dormancy to active growth. In a number of cancer cell lines, uPAR expression correlates with the basal activity of ERK (13, 14) . Furthermore, the ratio of activity of ERK/p38 SAPK predicts cancer growth on chorioallantoic membranes (46, 47) . We have shown that autocrine signaling of uPA and uPAR prevents apoptosis of cancer cells (14) . The known function of PAI-1 is to inhibit the serine protease activity of uPA; however, the complex of uPA and PA1-1 sustains uPARinitiated signaling to ERK by recruiting a second receptor, the VLDL receptor, and thereby converts uPA into a MCF-7 cell mitogen (39) . Sustained ERK phosphorylation allows for nuclear localization and subsequent stabilization of c-Fos and other immediate early genes, which are necessary for S-phase entry (33) (34) (35) .
The EGFR has been implicated in signaling from uPAR to ERK; however, our previous studies suggest that the EGFR is not essential (26) . Alternative mechanisms by which the EGFR may function in uPAR-initiated cell signaling have not been described. Furthermore, to our knowledge, there is no previous evidence suggesting that the EGFR or any other uPAR coreceptor may be essential for a specific cellular response to uPA. The ability of the EGFR to promote cellular proliferation in response to uPA was not anticipated, because cell growth usually requires sustained ERK activation (33) (34) (35) , and EGFRpromoted ERK activation is typically transient (35) .
A major finding in this study is the ability of the EGFR to convert uPA into a mitogen in CHO cells without influencing the kinetics of ERK activation. We confirmed this observation by expressing EGFR transiently and stably in CHO cells. Furthermore, we have shown that the EGFR is essential for uPARpromoted cell growth in two separate breast cancer cell culture model systems: MDA-MB 468 cells treated with uPA and MCF-7 cells treated with uPA⅐PAI-1 complex. MDA-MB 468 cells express high levels of EGFR and moderately high levels of uPAR. MCF-7 cells express lower levels of both receptors (10, 28) . Our results suggest that activation of two distinct but complementary signaling pathways is essential for uPAR-promoted growth. Because dominant-negative MEK-1 antagonized growth in WT-EGFR-CHO cells, ERK activation or at least the basal level of ERK activity is essential. Second, activation of STAT5b is essential. STAT5b is activated downstream of uPAR, only in EGFR-expressing cells, explaining why the EGFR is a necessary component of the uPAR MSRC when the uPA/uPAR system functions in promoting cancer cell proliferation.
Our model in which the EGFR and STAT5b activation are essential for uPA-promoted cell proliferation was supported by multiple lines of evidence. STAT5b was tyrosine-phosphorylated in response to uPA only in EGFR-expressing cells. A dominant-negative form of STAT5b functioned as an antagonist of uPA-promoted growth. Furthermore, EGFR mutants that are unable to support STAT5b activation (EGFR-Y845F and EGFR-K721A/Y845F) failed to support proliferation in response to uPA. The same mutants also functioned as dominantnegatives in uPA-treated WT-EGFR-CHO cells. Tyr-845 in the EGFR is phosphorylated by c-Src in the pathway by which STAT5b is activated (28) and c-Src is known to be activated upstream of ERK in uPA-treated cells (15) . Thus, it is possible that c-Src is activated by integrin-associated proteins within the uPAR MSRC and then targets Tyr-845 in the EGFR as one of its substrates.
Initially, we were surprised to find that DIP-uPA promotes growth in WT-EGFR-CHO cells because ERK phosphorylation in response to DIP-uPA appeared transient. Phospho-ERK levels returned to near or below baseline in 30 min. We assumed that the duration of ERK activation is insufficient to support transition to S-phase. However, we subsequently resolved this issue by demonstrating for the first time that uPA signaling to ERK in CHO cells is biphasic. The second phase, although decreased in amplitude compared with that observed at 10 min, was sustained for at least 6 h. At the present time, we do not understand the factors that control the two-phase behavior. However, because we challenged cells with protease-inactivated uPA, our previously proposed mechanism, in which PAI-1 recruits the VLDL receptor to the uPAR MSRC and thereby sustains ERK activation (39) is not operational. The second phase of ERK phosphorylation, in uPA-treated WT-EGFR-CHO cells, may be due to shedding of EGFR ligands, which increases in a positive feedback cycle as a result of ERK activation (48, 49) . CHO-K1 cells express low level of erbB2 (HER2) and erbB4, but not EGFR or erbB3 (50 -52). Thus, it is possible that increased shedding of erbB2 or erbB4 ligands may induce the second phase of ERK activation in CHO-K1 cells.
In EGFR-deficient CHO cells, a pertussis toxin-sensitive GPCR was necessary to couple uPAR to ERK, suggesting a role for FPRL-1 or a closely related GPCR, which has been strongly implicated as a member of the uPAR MSRCs (19) . Importantly, the EGFR did not displace the pertussis toxin-sensitive GPCR as an essential co-receptor. Thus, these two signaling co-receptors may function collaboratively as part of a single MSRC. The ability of the metalloprotease inhibitors, GM6001 and batimastat, to inhibit or totally block signaling from uPAR to ERK, in WT-EGFR-CHO cells, suggests that the previously described "triple membrane-passing signal" mechanism of EGFR transactivation may be operational. In this pathway, GPCRs transactivate the EGFR by activating transmembrane metalloproteases, such as ADAM-10 or ADAM-17, which then release membrane-anchored EGFR ligands (4, 5) . The mechanism by which GPCRs activate metalloproteases is unclear; however, a role for c-Src has been proposed (53) . Thus, an ADAM may represent a second target downstream of uPAR-activated Src, together with Tyr-845 of the EGFR.
Liu et al. (20) reported that uPA-associated uPAR interacts with ␣ 5 ␤ 1 and the EGFR to activate ERK in tumorigenic Hep3 cells. We have not been able to co-precipitate uPAR with the EGFR from extracts of WT-EGFR-CHO cells. The possibility that the triple membrane-passing signal mechanism is operational in WT-EGFR-CHO cells suggests that the EGFR does not necessarily need to be physically associated with uPAR to function as a member of the uPAR signaling system. However, because ERK is activated quickly after adding uPA, the various steps leading from uPAR ligation to ERK activation also must occur very rapidly. Close proximity of uPAR, the EGFR, and its transmembrane ligands might be expected to facilitate rapid activation of cell signaling.
The goal of this study was to better understand the impact of cross-talk between uPAR and the EGFR. From our work, a model emerges in which the prognostic significance of the EGFR and uPAR in the same types of cancer may not be coincidental. Instead, expression of uPAR and overexpression of the EGFR may represent a particularly problematic combination based on the ability of these receptors to function synergistically to promote cancer cell growth. FIG. 11 . The EGFR is required for uPA⅐PAI-1 complex-induced MCF-7 cell growth. MCF-7 cells were plated in 96-well plates and cultured for 18 h in serum-containing medium. The cultures were then serum-starved for 4 h. Cells were pretreated with tyrphostin AG1478 (0.5 M) or vehicle for 2 h and then treated with DIP-uPA (10 nM) or uPA⅐PAI-1 complex (5 nM) for 48 h. The number of viable cells was determined by MTT assay before (0 h) and after (48 h) treatment with uPA or uPA⅐PAI-1 complex. Cell number is expressed as the percent increase in viable cells relative to that present at 0 h (mean Ϯ S.E., n ϭ 10).
